Partial
Partially Aligned
Patient Risk:
Low
Summary
Some mechanistic/clinical claims (e.g., class, delayed postprandial glucose) are supported by the provided excerpts, but multiple claims about acarbose production/manufacturing patents and patent exclusivity are not supported by the prescribing information excerpts and are not label-relevant. Additionally, one pharmacology claim is broadly consistent but partly over-specific relative to the excerpted label language.
Category Scores
Accurate Statements
Acarbose is an alpha-glucosidase inhibitor used to treat type 2 diabetes.
Supported by Sections 1 (adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus) and 12 (enzyme inhibition of intestinal alpha-glucosidase hydrolase enzymes).
Acarbose is in the class of alpha-glucosidase inhibitors.
Supported by Section 5 (mentions alpha-glucosidase inhibitors) and Section 12 (competitive inhibition of intestinal alpha-glucoside hydrolase enzymes).
Acarbose works by slowing down the digestion of carbohydrates in the gut.
Partially supported by Section 12: delayed glucose absorption via inhibition of digestive enzymes (pancreatic alpha-amylase and intestinal alpha-glucoside hydrolase enzymes). The excerpt does not explicitly describe 'digestion of carbohydrates' in those exact terms, but the mechanism aligns with delayed carbohydrate/glucose absorption.
Acarbose reduces post-meal blood glucose spikes.
Supported by Section 12 (lowering of postprandial hyperglycemia) and Section 14 (one-hour postprandial glucose reductions).
Unsupported Statements
The biosynthesis of acarbose is primarily achieved through fermentation by microorganisms.
Not supported in the provided prescribing information excerpts (sections considered do not include manufacturing/biologic production details).
Acarbose biosynthesis is specifically achieved through fermentation by Actinoplanes utahensis.
Not supported in the provided prescribing information excerpts.
In acarbose biosynthesis, enzymatic conversion of starting materials produces the complex oligosaccharide structure of acarbose.
Not supported in the provided prescribing information excerpts.
Patents have been issued covering aspects of acarbose production, including the fermentation process and purification methods.
Not supported in the provided prescribing information excerpts.
Patents have been issued covering specific crystalline forms of acarbose.
Not supported in the provided prescribing information excerpts.
Patent exclusivity for acarbose has largely expired in major markets.
Not supported in the provided prescribing information excerpts.
New patents related to improved manufacturing processes, novel formulations, or combination therapies for acarbose may still be active.
Not supported in the provided prescribing information excerpts.
Disputes involving acarbose can arise over new patents covering process improvements or specific formulations.
Not supported in the provided prescribing information excerpts.
Contradictions
Important Omissions
No label-based support was possible for manufacturing/fermentation/patent/exclusivity claims because the provided prescribing information excerpts do not address these topics.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label-misaligned claims are primarily non-clinical (manufacturing/patents) and do not directly alter dosing, contraindications, warnings, or monitoring. One mechanistic claim is broadly consistent with delayed postprandial glucose effects but is not explicitly stated in the label excerpt using the exact phrasing.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple statements about fermentation, Actinoplanes utahensis, crystalline forms, and patent exclusivity/disputes are not supported by the provided PRECOSE prescribing information excerpts.
Suggested Improvement
Limit claims to label-supported clinical content (indication, mechanism, postprandial glucose reduction). Remove or qualify non-label manufacturing/patent assertions since they are not addressed in the provided FDA label excerpts.